Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial | |
Witzig, T. E.; Tobinai, K.; Rigacci, L.; Ikeda, T.; Vanazzi, A.; Hino, M.; Shi, Y.; Mayer, J.; Costa, L. J.; Bermudez Silva, C. D. | |
2018 | |
卷号 | 29期号:3页码:707-714 |
关键词 | Adjuvant therapy everolimus large cell lymphoma |
ISSN号 | 0923-7534 |
DOI | 10.1093/annonc/mdx764 |
URL标识 | 查看原文 |
收录类别 | SCIE ; PUBMED |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6361328 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Witzig, T. E.,Tobinai, K.,Rigacci, L.,et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial[J],2018,29(3):707-714. |
APA | Witzig, T. E..,Tobinai, K..,Rigacci, L..,Ikeda, T..,Vanazzi, A..,...&Cavalli, F..(2018).Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.,29(3),707-714. |
MLA | Witzig, T. E.,et al."Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial".29.3(2018):707-714. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论